Oncology revenue reached $22.4 billion in 2024, with Tagrisso, Lynparza, and Enhertu delivering strong growth. Enhertu's revenue grew 54% in Q4, supported by expanded indications, including HER2 low ...

In a significant initiative to promote investor awareness and protect the interest of the investors in the securities m ...

AstraZeneca said it forecasts sales and earnings growth this year after fourth-quarter results beat expectations, as strength in its oncology business offset weak China sales, but warned of a ...